Bristol-Myers Squibb Company (BMY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bristol-Myers Squibb Company (BMY) trades at $58.13 with AI Score 88/100 (Grade A+). Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and marketing innovative medicines. Market cap: $118.71B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026BMY stock analysis for 2026: Analysts have set a consensus price target of $63.91 for Bristol-Myers Squibb Company, suggesting 9.9% upside from the current price of $58.13. The AI MoonshotScore is 88/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
BMY: 5/7 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Bristol-Myers Squibb Company (BMY) Healthcare & Pipeline Overview
Bristol-Myers Squibb is a global biopharmaceutical company distinguished by its diverse portfolio of innovative medicines, particularly in oncology, hematology, immunology, and cardiovascular diseases. With a strong focus on research and development, BMY operates in a competitive landscape, delivering therapies to wholesalers, distributors, pharmacies, and healthcare providers worldwide.
What Is the Investment Thesis for BMY?
Bristol-Myers Squibb presents a compelling, albeit complex, investment case. With a market capitalization of $118.71B and a P/E ratio of 15.6, the company demonstrates established profitability, supported by a 15.0% profit margin and a robust 68.7% gross margin. A key value driver is BMY's diverse product portfolio, which mitigates risk across various therapeutic areas. Growth catalysts include the continued expansion of key drugs like Opdivo and Eliquis, as well as the introduction of newer products such as Zeposia and Breyanzi. However, investors may want to evaluate potential risks, including patent expirations for key drugs and the inherent uncertainties of pharmaceutical research and development. The company's dividend yield of 4.45% offers an attractive return for income-seeking investors, but future dividend growth will depend on sustained earnings and cash flow.
Based on FMP financials and quantitative analysis
BMY Key Highlights
- Market Cap of $118.71B indicates a substantial and stable company within the pharmaceutical industry.
- P/E Ratio of 15.6 suggests the company is reasonably valued compared to its earnings.
- Profit Margin of 15.0% demonstrates effective cost management and strong pricing power.
- Gross Margin of 68.7% highlights the high value-added nature of the company's pharmaceutical products.
- Dividend Yield of 4.45% provides an attractive income stream for investors, reflecting the company's commitment to shareholder returns.
Who Are BMY's Competitors?
BMY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PFE Pfizer Inc. | $24.32 | +1.84% | $138.61B | 64 |
| SNY Sanofi | $43.16 | +3.68% | $103.77B | 58 |
| VRTX Vertex Pharmaceuticals Incorporated | $528.04 | +6.03% | $134.02B | 99 |
| CVS CVS Health Corporation | $104.72 | -0.09% | $133.62B | 74 |
| GSK GSK plc | $53.66 | +4.60% | $107.47B | 61 |
| MRK Merck & Co., Inc. | $129.52 | +3.31% | $319.89B | 64 |
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BMY's Key Strengths?
- Diverse product portfolio across multiple therapeutic areas.
- Strong research and development capabilities.
- Global presence and established distribution network.
- Robust patent protection for key products.
What Are BMY's Weaknesses?
- Reliance on key products with potential patent expirations.
- Exposure to regulatory and pricing pressures.
- High research and development costs.
- Competition from generic drug manufacturers.
What Could Drive BMY Stock Higher?
- Clinical trial results for key pipeline drugs in oncology and immunology by Q4 2026.
- Continued expansion of Opdivo and Eliquis into new indications.
- Strategic acquisitions and partnerships to expand product portfolio.
What Are the Key Risks for BMY?
- Insider selling — insiders were net sellers of roughly $2.2M recently.
- Patent expirations for key products, leading to generic competition.
- Regulatory changes and pricing pressures impacting profitability.
- Clinical trial failures for pipeline drugs.
- Competition from other pharmaceutical companies.
- Product liability lawsuits and other legal challenges.
What Are the Growth Opportunities for BMY?
- Expansion of Oncology Portfolio: Bristol-Myers Squibb has significant growth potential in the oncology market, driven by its key drug, Opdivo, and newer therapies like Breyanzi. The global oncology market is projected to reach $400 billion by 2030, presenting a substantial opportunity for BMY to increase its market share through continued clinical development and commercialization of innovative cancer treatments. Success in this area will depend on positive clinical trial outcomes and regulatory approvals.
- Growth in Immunology: With products like Orencia and Zeposia, Bristol-Myers Squibb is well-positioned to capitalize on the growing immunology market. The increasing prevalence of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis is driving demand for effective therapies. The global immunology market is expected to reach $150 billion by 2028, offering BMY a significant opportunity to expand its presence through new indications and formulations.
- Cardiovascular Disease Therapies: Eliquis, a leading oral anticoagulant, continues to be a key growth driver for Bristol-Myers Squibb in the cardiovascular market. As the global population ages, the incidence of atrial fibrillation and venous thromboembolism is expected to increase, driving demand for effective anticoagulation therapies. The cardiovascular drug market is projected to reach $200 billion by 2027, providing BMY with continued growth opportunities.
- Emerging Markets Expansion: Bristol-Myers Squibb has the opportunity to expand its presence in emerging markets, where healthcare spending is increasing and access to innovative medicines is improving. Countries like China, India, and Brazil represent significant growth opportunities for BMY's key products. Successful expansion will require strategic partnerships, regulatory approvals, and effective distribution networks. This expansion can contribute significantly to BMY's long-term revenue growth.
- Strategic Acquisitions and Partnerships: Bristol-Myers Squibb can drive growth through strategic acquisitions and partnerships that expand its product portfolio and pipeline. By acquiring or licensing innovative therapies from other companies, BMY can accelerate its growth in key therapeutic areas. The company has a history of successful acquisitions, and continued strategic deal-making will be essential for maintaining its competitive position and driving long-term value creation. These partnerships can provide access to cutting-edge research and development.
What Opportunities Does BMY Have?
- Expansion into emerging markets.
- Development of new therapies for unmet medical needs.
- Strategic acquisitions and partnerships.
- Growth in personalized medicine and targeted therapies.
What Threats Does BMY Face?
- Patent expirations and generic competition.
- Regulatory changes and pricing pressures.
- Clinical trial failures.
- Product liability lawsuits.
What Are BMY's Competitive Advantages?
- Patent protection for key pharmaceutical products.
- Strong brand reputation and established relationships with healthcare providers.
- Extensive research and development capabilities.
- Diverse product portfolio across multiple therapeutic areas.
What Does BMY Do?
Founded in 1887, Bristol-Myers Squibb (BMY) has evolved into a leading global biopharmaceutical company dedicated to discovering, developing, licensing, manufacturing, and marketing innovative medicines. The company's origins trace back to two separate entities: the Bristol-Myers Company and E.R. Squibb & Sons, which merged in 1989. BMY's therapeutic focus spans several key areas, including oncology, hematology, immunology, fibrotic diseases, neuroscience, and cardiovascular diseases. Its diverse product portfolio includes notable drugs such as Revlimid, an oral immunomodulatory drug for multiple myeloma; Eliquis, an oral inhibitor used to reduce the risk of stroke; Opdivo, an anti-cancer therapy; and Orencia, for rheumatoid and psoriatic arthritis. Other key products include Sprycel, Yervoy, Abraxane, Reblozyl, Empliciti, Zeposia, Breyanzi, Inrebic, and Onureg. BMY markets its products globally through a network of wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies, solidifying its position in the competitive pharmaceutical market. The company is headquartered in Princeton, New Jersey, and employs over 34,100 individuals worldwide.
What Products and Services Does BMY Offer?
- Discovers novel biopharmaceutical products through research and development.
- Develops and formulates pharmaceutical drugs for various therapeutic areas.
- Licenses pharmaceutical products for commercialization.
- Manufactures biopharmaceutical products on a global scale.
- Markets and sells biopharmaceutical products to healthcare providers and patients.
- Offers therapies for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and COVID-19 diseases.
- Distributes products through wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
How Does BMY Make Money?
- Develops and patents innovative pharmaceutical products.
- Generates revenue through the sale of prescription drugs.
- Invests heavily in research and development to discover new therapies.
- Markets and distributes products globally through various channels.
What Industry Does BMY Operate In?
Bristol-Myers Squibb operates within the highly competitive and regulated pharmaceutical industry. The industry is characterized by intense research and development efforts, stringent regulatory requirements, and patent protection. Market trends include a growing demand for innovative therapies, particularly in oncology, immunology, and cardiovascular diseases. The competitive landscape includes major players such as Pfizer Inc. (PFE), Sanofi (SNY), and Vertex Pharmaceuticals Incorporated (VRTX). BMY differentiates itself through its diverse product portfolio and focus on specialized therapeutic areas. The global pharmaceuticals market is projected to reach trillions of dollars by 2026, driven by an aging population and increasing prevalence of chronic diseases.
Who Are BMY's Key Customers?
- Wholesalers and distributors of pharmaceutical products.
- Pharmacies and retailers that dispense prescription drugs.
- Hospitals and clinics that administer treatments to patients.
- Government agencies and healthcare organizations.
Net buyingInsider Activity
Over the past six months, Bristol-Myers Squibb Company insiders filed 30 SEC Form 4 transactions — 10 sales and 20 purchases. On net that is roughly 84K shares acquired (about $2.2M) — insiders putting money in tends to read as conviction.
FY2026 estForward Outlook
Wall Street analysts project Bristol-Myers Squibb Company revenue of about $47.30B for fiscal 2026, with EPS near $6.32. The estimate reflects 20 contributing analysts.
F-Score 8/9Financial Health
Bristol-Myers Squibb Company's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.44 places it in the grey zone, a middle ground that warrants monitoring.
ROE 39%Key Financial Metrics
Return on equity for Bristol-Myers Squibb Company stands at 39.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.4%, showing how much profit it generates from its asset base. BMY trades at a trailing price-to-earnings ratio of 15.62, below the Healthcare sector average of ~23x. Its free cash flow yield is 10.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.4%, the inverse of the P/E and a quick read on earnings relative to price.
Bristol-Myers Squibb Company (BMY) Valuation Context
Valued at $118.71B, BMY is classified as a large-cap stock. Relative to its peer group, BMY's quantitative score of 88/100 is above the peer average of 71/100.
BMY Revenue & Earnings Trend
In Q1 2026, BMY generated $11.49B in top-line revenue, marking a sequential decrease of 8.1%. The company recorded net income of $2.68B, with diluted EPS of $1.31. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, BMY averaged $0.89 in diluted EPS.
Company Profile
Bristol-Myers Squibb Company operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Princeton, US. The company is led by CEO Christopher S. Boerner. BMY has traded publicly since 1972.
BMY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in strong upcoming performance.
- Community sentiment has turned increasingly positive, with discussions focusing on recent drug approvals and their potential market impact.
- Analysts have praised Bristol-Myers' robust pipeline, highlighting innovative treatments that could drive growth in the coming years.
- Market perception is bolstered by strategic partnerships that enhance research capabilities and broaden market reach.
Bear Case
- Concerns over patent expirations on key drugs have surfaced, raising questions about future revenue streams.
- Some community members express skepticism regarding the sustainability of recent gains, citing potential market volatility.
- Negative sentiment has emerged around competition from generics, which could pressure pricing and margins in the near term.
- Recent regulatory challenges have caused uncertainty, leading to cautious views among analysts about the company's operational resilience.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
From the Earnings Call
“We are reaffirming our financial guidance for the full year of 2026. Based upon the first quarter results and our current projections, we see our financial performance tracking towards the upper end of our established revenue and EPS guidance from us.”
— David Elkins, CFO
“In the quarter, growth portfolio sales were up 9% year-over-year with contributions from a broad range of assets, including Reblozyl, Breyanzi, [indiscernible], Opdualag, Qvantig and Cobenfy.”
— Christopher Boerner, CEO
BMY Q1 FY2026 earnings call transcript · 2026-04-30
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $11.49B | $2.68B | $1.31 |
| Q4 2025 | $12.50B | $1.09B | $0.53 |
| Q3 2025 | $12.22B | $2.20B | $1.08 |
| Q2 2025 | $12.27B | $1.31B | $0.64 |
Based on FMP financials and quantitative analysis
BMY Latest News
-
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
Yahoo! Finance: BMY News · Jul 3, 2026
-
2 Cash-Producing Stocks Worth Investigating and 1 Facing Headwinds
Yahoo! Finance: BMY News · Jul 3, 2026
-
Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes
seekingalpha.com · Jul 3, 2026
-
Sector Update: Healthcare
MT Newswires · Jul 2, 2026
BMY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BMY.
Price Targets
Consensus target: $63.91
BMY MoonshotScore
What does this score mean?
The MoonshotScore rates BMY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
2 Cash-Producing Stocks Worth Investigating and 1 Facing Headwinds
Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes
Sector Update: Healthcare
Latest Bristol-Myers Squibb Company Analysis
Paladin Surges 5.38% on Heightened Market Activity
3 min readIntel (INTC) Drops 5.25% Amid Broader Tech Sell-Off, Nasdaq 100 Falls 1.61%
3 min readCybersecurity Stocks Surge: CRWD Up 4.30%, HCWB Skyrockets 153.77%
2 min readGOOGL Jumps 4.01% Amid AI Chip Competition with Nvidia
3 min readSavara Shares Plunge 6.81% as Investigation Announced
3 min readLeadership: Christopher S. Boerner
CEO
Christopher S. Boerner serves as the Chief Executive Officer of Bristol-Myers Squibb. His career within the pharmaceutical industry spans several leadership roles, demonstrating a deep understanding of the complexities of drug development, commercialization, and market access. Boerner's background includes significant experience in strategic planning, business development, and global operations. Prior to his CEO appointment, he held various executive positions within Bristol-Myers Squibb, contributing to the company's growth and strategic direction. His educational credentials include advanced degrees in business and healthcare management.
Track Record: Since assuming the role of CEO, Christopher Boerner has focused on driving innovation, expanding the company's pipeline, and enhancing operational efficiency. Key milestones under his leadership include strategic acquisitions aimed at bolstering BMY's portfolio and pipeline, as well as initiatives to streamline operations and improve profitability. Boerner has also emphasized the importance of patient access and affordability, working to ensure that BMY's medicines reach those who need them most.
Common Questions About BMY (Healthcare)
What does Bristol-Myers Squibb Company do?
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, licensing, manufacturing, and marketing innovative medicines. The company's diverse portfolio addresses critical unmet needs in oncology, hematology, immunology, fibrotic diseases, neuroscience, and cardiovascular diseases. Key products include Revlimid, Eliquis, and Opdivo, which are used to treat multiple myeloma, reduce the risk of stroke, and combat various forms of cancer, respectively. BMY sells its products to wholesalers, distributors, pharmacies, hospitals, clinics, and government agencies worldwide, contributing to improved patient outcomes and healthcare advancements.
What do analysts say about BMY stock?
Analyst consensus on Bristol-Myers Squibb (BMY) stock is mixed, reflecting the company's complex financial profile and growth prospects. Key valuation metrics, such as the P/E ratio of 15.6, suggest that the company is reasonably valued compared to its earnings. Growth considerations include the continued expansion of key drugs like Opdivo and Eliquis, as well as the introduction of newer products. However, analysts also note potential risks, including patent expirations and regulatory pressures. Overall, analyst recommendations range from hold to buy, with price targets reflecting expectations for moderate growth and stable profitability.
What are the main risks for BMY?
Bristol-Myers Squibb faces several key risks inherent to the pharmaceutical industry. Patent expirations for blockbuster drugs like Revlimid pose a significant threat, as generic competition can erode sales and profitability. Regulatory changes and pricing pressures, particularly in the United States, can also impact revenue and margins. Clinical trial failures represent another risk, as the company invests heavily in research and development, and not all pipeline drugs will succeed. Additionally, BMY faces competition from other pharmaceutical companies and is subject to product liability lawsuits and other legal challenges. These risks require careful management and mitigation strategies to ensure long-term success.
What are the key factors to evaluate for BMY?
Bristol-Myers Squibb Company (BMY) holds an AI score of 88/100 (high). P/E: 15.6x vs the S&P 500's ~20-25x. Analysts target $63.91 (+10%). Not financial advice.
How frequently does BMY data refresh on this page?
BMY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BMY's recent stock price performance?
Bristol-Myers Squibb Company (BMY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio across multiple therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BMY overvalued or undervalued right now?
Bristol-Myers Squibb Company (BMY) trades at 15.6x earnings. Analysts target $63.91 (+10%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BMY?
Before investing in Bristol-Myers Squibb Company (BMY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and company filings.
- Financial data is as of 2026-05-10.
- Future performance is subject to market conditions and company-specific factors.